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ABSTRACT  
Background: Chronic kidney disease (CKD) patients often have a chronic fatigue and lower QoL, thus may increase morbidity and mortality in 
CKD patients. Objective: The objective was to identify the benefit and safety of administration of intravenous vitamin B combination to 
reducing fatigue, measure the prevalence of fatigue and QoL in CKD patients. Method: This study was an observational non control study for 4 
weeks in CKD patients with routine hemodyalisis 2 times/week. Every subject has a routine administration of intravenous vitamin B 
combination, consist of 100 mg vitamin B1, 100 mg vitamin B6, and 5000 mcg vitamin B12, after each hemodyalisis. Visual analogue scale (VAS) 
used to measure the degree of fatigue. QoL measured using SF-8 questionnaire, consist of total, physical (PCS), and mental component (MCS). 
Results: The prevalence of fatigue is high. The mean VAS score was 3.4±2.1 at baseline and there were 46.7% subjects with VAS score above the 
mean VAS score. After 4 weeks administration of vitamin B combination intravenously, the mean VAS score was decreasing from 3.4 to 2.7. The 
prevalence of fatigue was decreasing from 46.7% to 41%. This shifting was statistically significant (p:0.008). There was a score reduction in 
total component (20.19±4.8 to 19.29±4.9), PCS (13.44±3.1 to 12.99±3.5), and MCS (6.75±2.1 to 6.31±1.9). This score reduction indicated a 
better QoL. However, the reduction was not statistically significant. Conclusion: The prevalence of fatigue is high. Intravenous vitamin B 
combination considered to be effective and safe to reducing the degree of fatigue in CKD patients. 
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INTRODUCTION 
There is increasing awareness of the high symptom burden 
and impaired health related quality of life (QoL) experienced 
by patients with chronic kidney disease (CKD).1 Patients 
with CKD often experience a wide variety of symptoms as 
disease progresses.2 Patients with routine hemodyalysis 
often accompanied by various symptoms such as fatigue, 
pain, muscle cramps, difficulty with sleep, and sexual 
dysfunction.3 Fatigue is one of the most prevalent symptoms 
in CKD with dyalisis.4,5 Fatigue defined as a complex, 
multidimensional, and multifactorial phenomenon, which 
has been defined as ‘extreme and persistent tiredness, 
weakness or exhaustionmental, physical or both’.6 According 
to Gordon, et al. (2011) approximately 86% of patients 
experience postdialysis fatigue ranging from mild-to-
severe.7 
Chronic fatigue impacts patients' daily functioning, QoL, and 
delays recovery after hemodialysis.8 Fatigue has been 
associated with increases the risk of cardiovascular events, 
negatively influences survival, and increased risk for 
mortality in hemodialysis patients.8-10 Very little data are 
available concerning the QoL of patients with end-stage 
renal disease maintained on dialysis in the developing 
world.11 Therefore, it is important to delve deeper into this 
topic. 
Vitamin deficiencies, such as vitamin B1, vitamin B6, and 
vitamin B12, are common in people with advanced renal 
failure who do not take nutritional supplements and may be 
the cause of fatigue in CKD patients.11  
OBJECTIVES 
The main objective of this study is to identify the benefit of 
intravenous vitamin B combination to reduce fatigue in CKD 
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patients. The secondary objective is to measure the 
prevalence of fatigue and QoL in CKD patients. This study 
also identify the safety of intravenous vitamin B combination 
in CKD patients. 
METHODS 
An observational non control study has been held at 
hemodyalisis center of Bethesda Hospital and Panti Rapih 
Hospital, Yogyakarta, Indonesia. This study conducted from 
August to October 2018. The minimum subjects requirement 
in this study were 120 subjects. Each subject would be 
followed for 4 weeks.  
Every male or female, age >18 years, diagnosed with CKD, 
and has a routine hemodyalisis two times per week with 
time interval between each hemodyalisis was 3 to 4 days 
was included. The sequence of hemodyalisis per week 
reffered as “first hemodyalisis” and “second hemodyalisis” in 
order to easy to describe. Subjects who did not willing to join 
the study, has a known hypersensitivity to vitamin B 
combination or its composition, participation in other 
clinical trial in the last 1 month, incompetent to give a 
consent and to answer the questionnaires, pregnant or has a 
plan to get pregnant would be excluded. 
Every hemodyalisis subject in Bethesda Hospital and Panti 
Rapih Hospital has a routine intravenous injection of vitamin 
B combination, consist of 100 mg vitamin B1, 100 mg vitamin 
B6, and 5000 mcg vitamin B12, after each hemodyalisis. 
Subject with a history of routine vitamin B combination 
supplementation was not allowed in this study. Each subject 
participating in this study have to signed an informed 
consent form. 
Demographic data, medical history, co-treatment, fatigue 
scale, and the presence of adverse event were assessed in 
this study. Demographic data includes: age, gender, marital 
status, educational degree, and working status. Age classified 
into >70, 70-61, 60-51, 50-40, and <40 years. Marriage 
status differed into married and not married, which is 
including single and divorce. Educational degree classified 
into undereducated (unschooled or elementary school), high 
school (junior or senior high school), and diploma, 
bachelor’s degree, or higher. Working status differentiated 
into working and unemployment. 
VAS in this study has been used to measure the intensity of 
fatigue. A straight horizontal line of 10 cm was made, 0 at 
the left end reffered as “no fatigue at all” and 10 at the right 
end reffered as “complete exhaustion”. Subjects asked to 
mark the line at the point that they feel represent their 
current fatigue state. The VAS score was determined by 
measuring in centimeters from the left end to the mark. The 
VAS score measured at visit I (before the first hemodyalisis), 
visit II (2 weeks after visit I, after the second hemodyalisis), 
and visit III (2 weeks after visit II, after the second 
hemodyalisis). The VAS score reduction would be test for 
normality using Kolmogorov-Smirnov and continued using 
paired t test or Wilcoxon test.  Delta (Δ) VAS I – II and Δ VAS 
I – III defined as the shifting of VAS score from the first week 
to the second week and from the first week to fourth week. 
Other variables (age, gender, marital status, educational 
degree, and working status) were analyzed using Kruskal 
Wallis test or Mann Whitney U Test to identify other 
contributing factor(s) to VAS score reduction from first week 
to last week. The significant level was set at p < 0.05. 
QoL measured using SF-8 questionnaire. The questionnaire 
contains 8 questions about daily physical and mental status. 
Each question has 5 or 6 answer choices which is scored 1 to 
5 or 6 consecutively. Questions 1 to 5  consist of general 
health perception, physical functioning, physical role 
functioning, bodily pain, vitality. The final results will be 
summarized into physical component (PCS). Question 6 to 8 
consist of social social role function, mental health, and 
emotional role functioning. The final results will be 
summarized into mental component (MCS). A higher score of 
PCS and MCS indicates a worse QoL. QoL measured at visit I 
and visit III. 
Evaluation of adverse event in this study was done at the 
second and fourth week. Adverse event would be differed 
into: adverse event related to vitamin B combination and not 
related to vitamin B combination. Every adverse event 
would be recorded, reported, and handled according to 
management protocol in each study center. The severity of 
adverse event would be evaluated to determine the needed 
of hospitalization.  
Ethical clearance process was done in Duta Wacana 
Christian University School of Medicine Ethical Research 
Committee. The number of ethical clearance 
614/C.16/FK/2018. As this study used a primary data, 
informed consent process will be made very clearly. Each 
subject who refuse to be involved in this study are not 
required to explain their reason and will not affect their 
therapy. All data in this study will be classified and used only 
for research purposes. 
RESULTS 
Total of 122 subjects included in this study. Subjects 
dominated by male (63.9%) aged between 51-60 years 
(31.3%). Most subjects are married, well educated, and have 
an occupation. Anemia and hypertension were the common 
comorbidities in subjects.
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Table 1. Characteristics of Subjects at Baseline 
Characteristics 
Number of 
Subjects (n=122) 
% 
Gender: 
Male 
 
78 
 
63.9 
Female 44 36.1 
Mean age  51.7 ± 12.6 years 
Age 
     >70 
     61-70 
     51-60 
     40-50 
     <40 
 
25 
25 
38 
31 
3 
 
20.5 
20.5 
31.3 
25.4 
2.5 
Marital status 
     Married 
     Not married 
 
101 
21 
 
82.8 
17.2 
Educational background 
     Undereducated 
     High school 
    Diploma, bachelor degree or higher 
 
12 
53 
57 
 
9.8 
43.4 
46.7 
Working history 
     Working 
     Unemployment 
 
96 
26 
 
78.7 
21.3 
Medical history: 
Hypertension 
 
105 
 
86.1 
Diabetes Mellitus 41 33.6 
Stroke 9 7.4 
Cardiovascular disease 32 26.2 
Congenital kidney disease 2 1.6 
Urinary tract calculus 9 7.4 
Urinary tract infection 5 4.1 
Anemia 106 86.9 
Dyslipidemia 4 3.3 
 
 
Degree of fatigue assessed using VAS. The prevalence of 
fatigue was high. At the baseline, 46.7% subjects has VAS 
score above mean VAS score (mean VAS score at baseline: 
3.4 ± 2.1). Improvement on degree of fatigue was shown in 
this study after administration of intravenous vitamin B 
combination. The number of subjects who did not fatigue at 
all (indicate by VAS score 0) was increasing from the first to 
the last week : 3 subjects at the first week, 5 subjects at the 
second week, and 7 subjects at the last week. Mean VAS 
score was decrease gradually from the first week to the last 
week, as shown in table 2. The maximum VAS score was also 
decrease from the first week to the fourth week. 
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Table 2. VAS for Fatigue 
Visit Mean Score Min Score Max Score 
Visit I 3.4 0 9.3 
Visit II 2.9 0 10 
Visit III 2.7 0 8.8 
 
The prevalence of fatigue was decreasing, from 46.7% at 
baseline to 41% at the last week. Mean VAS score reduction 
was higher at ΔVAS I – III compared to ΔVAS I – II (Table 3). 
The degree of VAS score reduction (ΔVAS) was 64.4% from 
baseline to the second week and 62.4% from baseline to the 
fourth week. The reduction of VAS score from the first to the 
last week was statistically significant (p: 0.008). 
 
 
Table 3. VAS Score Reduction 
Visit Mean Reduction Score 
Percentage of 
Reduction Score 
p 
ΔVAS I – II 0.4 ± 1.9 64.4% 0.054 
ΔVAS I – III 0.7 ± 2.3 62.4% 0.008 
ΔVAS 1 – 2: the shifting of VAS score from the first week to the second week; ΔVAS 1 – 4: the shifting of VAS score from the first 
week to the fourth week 
 
Further analysis on other variables were made to identify 
other factors influencing the presence of fatigue. Age, 
gender, marital status, working history, educational 
background, and medical history were not  related to fatigue 
(Table 4).
 
Table 4. Analysis on Variables 
Variables Mean VAS Score p 
Gender  0.712 
    Male 3.4 ± 2.1  
    Female 3.5 ± 2.1  
Age  0.503 
    >70 2.9 ± 0.3  
    61-70 3.1 ± 2.2  
    51-60 3.6 ± 2.1  
    40-50 3.5 ± 2.3  
    <40 3.6 ± 1.9  
Marital status  0.789 
    Married 3.3 ± 2.1  
    Not married 3.8 ± 1.9  
Educational background  0.657 
    Undereducated 2.9 ± 1.9  
    High school 3.3 ± 2.0  
Diploma, bachelor degree or higher 3.7 ± 2.2  
Working history  0.147 
    Working 3.4 ± 2.0  
    Unemployment 3.2 ± 2.3  
Medical history   
    Hypertension 3.5 ± 2.1 0.627 
    Diabetes mellitus 3.7 ± 2.2 0.346 
    Cardiovascular disease 3.9 ± 2.2 0.158 
    Stroke 3.8 ± 3.2 0.786 
    Congenital kidney disease 1.1 ± 1.1 0.119 
    Urinary tract calculus 3.0 ± 2.3 0.329 
    Anemia 3.4 ± 2.2 0.955 
    Dyslipidemia 3.5 ± 1.8 0.385 
    Urinary tract infection 2.3 ± 0.9 0.795 
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Figure 1 showed the mean score for total component, PCS, 
and MCS. The higher score represent a worse QoL. QoL was 
improved after 4 weeks of treatment indicated by a lower 
mean score at the visit III. Physical problems were more 
common than mental problems among subjects.
 
 
Figure 1. Mean Score of Quality of Life 
After 4 weeks of treatment, there was a score reduction in 
total component, PCS, and MCS. Both PCS and MCS had a 
similar degree of score reduction (Table 5). This score 
reduction indicated an improvement of QoL. However, the 
score reduction was not statistically significant (Table 5). 
 
Table 5. Quality of Life Score 
QoL Component 
Mean Score  
Visit I 
Mean Score  
Visit III 
Mean Reduction Score p 
Total component 20.19 ± 4.8 19.29 ± 4.9 0.89 ± 5.4 0.070 
PCS 13.44 ± 3.1 12.99 ± 3.5 0.44 ± 3.6 0.181 
MCS 6.75 ± 2.1 6.31 ± 1.9 0.44 ± 2.5 0.065 
QoL: quality of life; PCS: physical components; MCS: mental components 
 
After observation for 4 weeks, there was no adverse event 
related to administration of intravenous vitamin B 
combination. There were two subjects who had a 
complication during this study and it was observed at the 
visit II. One subject had a history of recurrent dyspneu and 
worsened during the study. This subject diagnosed with 
acute lung oedema, needed to be hospitalized, and the 
frequency of hemodyalisis changed to three times per week. 
The second subject died during the study due to metabolic 
complication. After a further investigation, there was no 
correlation between those complication with the 
administration of vitamin B combination.  
DISCUSSION 
VAS is a general instrument to measure the degree of 
symptom, in many conditions or diseases.12-17 Some previous 
studies has already used VAS to measure the degree of 
fatigue.12-14,17 This study was also using VAS as the 
instrument to measure the degree of fatigue. 
The prevalence of fatigue is high as shown in this study. The 
mean VAS score was 3.4 ± 2.1 at baseline and there were 
46.7% subjects with VAS score above the mean VAS score. 
The prevalence of fatigue is different in many previous 
researches due to the difference of treatment modality and 
measurement instrument used. This current study was using 
VAS to evaluate fatigue severity in CKD patients. VAS was 
chosen in this study due to its simplicity and easy to use in 
daily practice. It is only takes a short time to mark the line. 
Previous study in 508 hemodyalisis patients showed the 
prevalence of fatigue using VAS was 81.5%.19 Fatigue 
measurement using fatigue assessment scale (FAS) on 129 
hemodyalisis patients showed that 47.3% subjects were 
fatigue and 13.7% were extremely fatigue.20 Excessive 
tiredness was the most common symptom (81%) in CKD 
patients stage I-V assessed using Leicester Uraemic Symptom 
Score.21 Fatigue assessment on 47 hemodyalisis patients for 
3 months using fatigue severity scale revealed the prevalence 
of fatigue was 44.7%.22 
This present study showed fatigue was more common in 
female, age 51-60 years, not married, well educated, 
working, and had a history of cardiovascular disease. 
However, those variables were not associated with fatigue. 
This result is similar to previous researches. Study in 92 
patients with ESRD showed no difference in level of fatigue 
between gender.23 Cross sectional study of 87 non-dialysis 
dependent CKD and 86 ESRD patients showed there was no 
association of age, gender, and diabetes with fatigue.1 
Observational cohort study on 109 subjects, anemia was not 
associated with fatigue.24 Research by Zyga, et al. (2015) also 
mention that marital status did not affect significantly any of 
the three fatigue indices in FAS.20 No correlation between 
20.1 
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6.8 
19.3 
12.9 
6.3 
0
5
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15
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25
Total
Component
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employment and fatigue as stated by O’Sullivan, et al. 
(2007).25 
Vitamin B combination used in this study contains 100 mg 
vitamin B1, 100 mg vitamin B6, and 5000 mcg vitamin B12. 
After administration of vitamin B combination intravenously, 
the mean VAS score was decreasing from 3.4 at baseline to 
2.7 at the last week and the prevalence of fatigue was 
decreasing, from 46.7% at baseline to 41% at the last week. 
This shifting is statistically significant (p: 0.008).  
Vitamin deficiencies are common in advanced renal failure 
and hemodyalisis patients.26,27 Patents with CKD have a risk 
for insufficient or deficient concentrations of vitamin B1.28 
CKD patients at stage 3 or worse are at an increased risk for 
deficient concentrations of vitamin B6.18 A hospital based 
cross sectional study on 50 CKD patients showed a high 
prevalence of vitamin B12 deficiency in CKD patients.29 
Fatigue has been associated with vitamin B deficiency, 
especially vitamin B12 deficiency.30 Based on literature 
review of 89 articles by Rusher and Pawlak (2013) shows 
fatigue is the common symptom cause by vitamin B12 
deficiency.31 Study by Tayyebi, et al. (2013) in 86 
hemodialysis patients shows the effectiveness of vitamin B12 
on the reduction of fatigue in hemodialysis patients.32 They 
recommend administration of intravenous injection of 100 
mcg/mL of vitamin B12 weekly after dialysis for hemodialysis 
patients. Research on 202 hemodyalisis patients conclude 
that nutritional supplementation, including vitamin B1, 
vitamin B6, vitamin B12, may modulate immune and 
autonomic dysfunction in ESRD patients undergoing 
hemodialysis.33 People with CKD regardless of whether they 
are predialysis or receiving either peritoneal or hemodialysis 
experience high levels of fatigue.34 
Physical problems were more common among CKD patients 
than mental problems (Figure 1). This result was similar to 
previous studies by Cruz, et al. and Kefale, et al. QoL 
decreased in all stages of kidney disease. A reduction in 
physical functioning, physical role functioning, and in the PCS 
was observed progressively in the different stages of kidney 
disease.35 Subject with CKD had reduction in several physical 
components (physical functioning [p: 0.03], bodily pain [p: 
0.004], vitality [p: 0.019])  than mental component (social 
functioning [p: 0.002]).36 
After 4 weeks of treatment, there was a score reduction in 
total component (20.19 ± 4.8 to 19.29 ± 4.9), PCS (13.44 ± 
3.1 to 12.99 ± 3.5), and MCS (6.75 ± 2.1 to 6.31 ± 1.9). This 
score reduction indicated an improvement of QoL. The lower 
score indicated a better QoL. However, the score reduction 
was not statistically significant (total component: 0.070, PCS: 
0.181, MCS: 0.065). 
CONCLUSION 
The prevalence of fatigue in this study is high. 
Administration of intravenous vitamin B combination two 
times per week after hemodyalisis proved to be effective and 
safe to reducing the degree of fatigue in CKD patients. The 
QoL in CKD patients was improved but not statistically 
significant. 
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